Meeting Banner
Abstract #1116

Assessing Response Heterogeneity following Radium 223 administration using Whole Body Diffusion Weighted MRI

Matthew David Blackledge1,2, Dow Mu Koh1,2, David J Collins1,2, Erica Scurr2, Julie Hughes2, Martin O Leach1,2, Chris Parker1,3, and Nina Tunariu1,2

1Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom, 2MRI Unit, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, 3Urology Department, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

Whole-Body Diffusion-Weighted-MRI is emerging as an imaging response biomarker in metastatic bone disease. Documentation of mixed therapeutic response is a key recommendation of the Prostate Cancer Working Group as recognition of coexistence of mixed response to therapy and clinical benefit. Radium-223 has shown efficacy in prostate cancer patients with symptomatic bone metastases. Monitoring Radium-223 therapy efficacy treatment is challenging, as Radium-223 administration can be associated with flare in pain, PSA and Bone Scan. These pilot data demonstrate that Radium-223 administration is associated with an increase in bone metastases ADC values together with a mixed response pattern.

This abstract and the presentation materials are available to members only; a login is required.

Join Here